Control and complications of intermittent heparin therapy
- PMID: 888052
Control and complications of intermittent heparin therapy
Abstract
A prospective study using an intermittent six hour method of heparin administration with control of subsequent dosage by the activated partial thromboplastin time revealed an over-all incidence of hemorrhagic complications of 12 per cent. If surgical patients are excluded, the incidence of hemorrhage falls to 4 per cent. This may be further reduced by monitoring the activated partial thromboplastin time within the therapeutic range. In no patient did thromboembolism recur while receiving heparin. It is suggested that this method provides adequate control of heparin therapy with an acceptable complication rate and adequate thromboembolic control and is cheaper to use than a continuous infusion.
Similar articles
-
Management of heparin therapy: Controlled prospective trial.N Engl J Med. 1975 May 15;292(20):1046-50. doi: 10.1056/NEJM197505152922002. N Engl J Med. 1975. PMID: 1091856 Clinical Trial.
-
Comparison of heparin and streptokinase in the treatment of venous thrombosis.Am Surg. 1975 Sep;41(9):511-19. Am Surg. 1975. PMID: 1101755 Clinical Trial.
-
Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.Arch Intern Med. 1997 Dec 8-22;157(22):2562-8. Arch Intern Med. 1997. PMID: 9531224 Clinical Trial.
-
Pathophysiology and treatment of deep-vein thrombosis and pulmonary embolism.Clin Pharm. 1985 May-Jun;4(3):279-96. Clin Pharm. 1985. PMID: 3891200 Review.
-
Managing the hemorrhagic complications of heparin therapy.Hematol Oncol Clin North Am. 1993 Dec;7(6):1281-9. Hematol Oncol Clin North Am. 1993. PMID: 8294317 Review.
Cited by
-
Intravenous heparin dosing: patterns and variations in internists' practices.J Gen Intern Med. 1993 Oct;8(10):536-42. doi: 10.1007/BF02599634. J Gen Intern Med. 1993. PMID: 8271085 Review.
-
Clinical pharmacokinetics of heparin.Clin Pharmacokinet. 1980 May-Jun;5(3):204-20. doi: 10.2165/00003088-198005030-00002. Clin Pharmacokinet. 1980. PMID: 6993082 Review.
-
ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.Br J Clin Pharmacol. 1987 Jun;23(6):667-75. doi: 10.1111/j.1365-2125.1987.tb03100.x. Br J Clin Pharmacol. 1987. PMID: 3606928 Free PMC article. Clinical Trial.
-
Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study.Mayo Clin Proc. 2009 Dec;84(12):1073-8. doi: 10.4065/mcp.2009.0220. Mayo Clin Proc. 2009. PMID: 19955244 Free PMC article.
-
Anticoagulants in older patients. A safety perspective.Drugs Aging. 1995 Jan;6(1):45-54. doi: 10.2165/00002512-199506010-00004. Drugs Aging. 1995. PMID: 7696778 Review.